Kornimate/medical-research-clean huggingface dataset:
coronally advanced flap with two different techniques for the treatment of multiple gingival recessions

Conditions: Gingival Diseases

Summary: this study compared the clinical outcomes of coronally advanced flap using two different surgical strategies in the treatment of multiple gingival recessions.

the objective of this split-mouth, randomized controlled trial was to compare the clinical outcomes of coronally advanced flap (caf) using two different surgical strategies in the treatment of multiple gingival recessions. recessions were randomly treated according to a split-mouth design by means of: caf with oblique interdental incisions (obl technique) or caf with horizontal interdental incisions (hor technique). marginal gingival recession (rec), clinical attachment level (cal), pocket probing depth (ppd), height of keratinized tissue (hkt) and thickness of keratinized tissue (tkt) were measured at baseline, 3 and 6 months after treatment. patient-centered outcomes concerning morbidity and improvement in the esthetic appearance were recorded using a visual analogue scale (vas).

Eligibility criteria:
inclusion criteria: * systemically healthy subjects * patients should have bilateral class i and ii mgrs (miller 1985) in maxillary tooth (at least three recession-type defects affecting adjacent teeth in each side of the maxilla). * at least 20 teeth and no sites with attachment loss and probing pocket depth (ppd) \> 3 mm. * full-mouth plaque and bleeding on probing of \< 20%. * involved tooth should present tooth vitality, absence of caries, restorations or extensive non-carious cervical lesion. exclusion criteria: * history of smoking. * antimicrobial and anti-inflammatory therapies in the previous 2 months. * previous mucogingival surgery at the region to be treated * systemic conditions that could affect tissue healing (e.g. diabetes). * use of orthodontic appliances.
optimizing intralesional triamcinolone dosing for hidradenitis suppurativa

Conditions: Hidradenitis Suppurativa

Summary: currently, there is limited evidence showing increased resolution of hs flares with higher doses of intralesional triamcinolone (iltac) as well as a difference in side effect profile between the doses. the goal of this study is to determine the efficacy of treating hs flares with iltac-10, iltac-20 and iltac-40 and to investigate the side effect profile for each dose.

a double-blinded, randomized, placebo-controlled study examining the relative efficacy of iltac-10, iltac-20, and iltac-40 versus placebo for acute flares of hs in subjects with moderate to severe hs. the duration of the study will be approximately 4 weeks for each enrolled patient and will include an initial screening/randomization/treatment visit and a 4-week follow-up period. during the initial visit, subjects who meet the study's eligibility criteria will be randomized to receive either iltac-10, iltac-20, iltac-40, or placebo in a 1:1:1:1 ratio. study subjects will then receive treatment or placebo. the follow-up period will be of 4 weeks and will consist of 3 phone calls and 1 live visit, including an end of study visit on week 4 after randomization.

Eligibility criteria:
inclusion criteria: * age \> 13 years old. * subject must voluntarily sign and date an informed consent, approved by an independent ethics committee / institutional review board. * subject is willing to comply with the procedures in this protocol. * the subject must be diagnosed with hs and receiving care at hsc * subjects with hidradenitis suppurativa physician global assessment (hs-pga) score between 2 and 5 * the subject must have an inflamed nodule or abscess at the time of enrollment. exclusion criteria: * the subject has an hs-pga score of 0 or 1 * the subject has received iltac less than 8 days prior to the initial visit. * the subject does not have capacity to consent to the study. * the subject is has taken systemic steroids at least 4 weeks prior to the time of enrollment. * the subject has a known allergy or history of adverse reaction to steroids. * the subject is pregnant. * subjects who have received a biologic therapy two weeks before and during the study period.
the effect of cataract surgery on sleep quality

Conditions: Cataract; Sleep

Summary: a cataract is a clouding of the crystalline lens inside the eye, which leads to a decrease in vision. it is the most prevalent, treatable cause of visual impairment and blindness in the world. cataract surgery with an intraocular lens (iol) implant is one of the most common and thought to be the most effective surgical procedure in any field of medicine. in this trial, the investigators aimed to evaluate the effect of cataract surgery on circadian rhythm and sleep as well as the effect of the blue light transmission characteristics of the implanted iol on sleep.

a prospective, randomized controlled study of 10000 participants(20000 eyes) with dense nucleus were enrolled. patients were assigned to two groups: group i: neutral iol implanted in eye while in group ii, blue-blocking iol was innovatively implanted in the eye. a cataract is a clouding of the crystalline lens inside the eye, which leads to a decrease in vision. it is the most prevalent, treatable cause of visual impairment and blindness in the world. cataract surgery with an intraocular lens (iol) implant is one of the most common and thought to be the most effective surgical procedure in any field of medicine. in this trial, the investigators aimed to evaluate the effect of cataract surgery on circadian rhythm and sleep as well as the effect of the blue light transmission characteristics of the implanted iol on sleep. patients enrolled into the study will be assessed in 3 months before the surgery and 3 months after the surgery.

Eligibility criteria:
inclusion criteria: * bilateral age-related cataract scheduled for cataract surgery exclusion criteria: * vision-impairing ophthalmic disease: glaucoma, amd, dr.et.al * severe systemic disease: diabetes, sleep disorder.et.al * vision-impairing complications: ruptured posterior capsule, persistent cornea edema.et.al
a study of shr-a1909 in subjects with advanced malignant tumors

Conditions: Advanced Malignant Cancer

Summary: this is an, open-label, multi-center, three-part phase i trial to evaluate the safety, pharmacokinetics and immunogenicity of shr-1909 and preliminary anti-tumor efficacy of shr-1909 in advanced malignant cancer.


Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) performance status of 0 or 1; * patients must have cytologically or histologically confirmed advanced malignant tumor, and must have failed standard treatment; * toxicities caused by prior anti-tumor treatments must have resolved to ctcae grade ≤ 1 prior to the first dose (except for alopecia or hypothyroidism treated with hormone replacement therapy or diabetes controlled with insulin); * adequate organ function. exclusion criteria: * with cns infiltration, or ascites requiring paracentesis or symptomatic pleural effusion; * received prior car t-cell therapy; * received allogeneic hematopoietic stem cell transplantation within 3 months prior to the start of study treatment, or with acute/chronic graft versus host disease; * with active infection or fever of unknown origin (\> 38.5 °c).
follicular challenge test to predict response to gnrh agonist triggering

Conditions: Infertility, Female

Summary: gnrh agonist triggering is used during art in order to reduce the risk of ohss. some studies described that in up to 5% of the cycles triggered with gnrh agonist, a lack of respone or suboptimal response was displayed. the investigators aim to asses the possibility to predict the respone to ovulation triggering by the response to decapeptyl in the follicular phase of the same cycle.

the investigators will use decapeptyl on day 2 of menstruation followed by antagonist protocol. hormonal proflie including e2, p, lh, fsh will be measured. lh surge and the rest of the hormonal profile will be compared to day after ovulation triggering.

Eligibility criteria:
inclusion criteria: * patients that undergo fertility preservation * patients planned to freeze embryos due to pgt or surrogacy --patients at high risk for ohss exclusion criteria: * poor ovarian response * known hypothalamic- pituitary dysfunction
neutrophil-to-lymphocyte ratio in predicting outcomes of patients with aneurysmal subarachnoid hemorrhage in a tertiary care hospital in nepal

Conditions: SAH (Subarachnoid Hemorrhage)

Summary: this study uses neutrophil-to-lymphocyte ratio to predict outcomes of patients with aneurysmal subarachnoid hemorrhage which will be beneficial in taking early decisions for surgery , patient counselling etc


Eligibility criteria:
inclusion criteria: * patients \> 18 years of age, of either genders, ethnicity and location who presented to the emergency department within 72 hours of the onset of symptoms who underwent surgical or interventional treatment for sah caused by a ruptured intracranial aneurysm exclusion criteria: * excluded patients with traumatic sah, history of infection or stroke within eight weeks, underlying cancer, severe kidney or liver disease, history of auto-immune or hematologic disorder lost to follow-up within three months and individuals declining informed consent.
wet-to-dry vs petrolatum & non-stick dressings after hidradenitis suppurativa surgery

Conditions: Hidradenitis Suppurativa; Surgical Wound

Summary: hidradenitis suppurativa (hs) is a chronic, severe, inflammatory skin disease associated with pain, drainage, odor, and disability characterized by recurring abscesses, nodules, and tunneling sinuses in intertriginous locations such as the groin, buttocks, and axillae. hs has more negative impact on patients' quality of life than all other common dermatologic diseases and is common, affecting \~1% of the general population, with higher risk for females (3:1) and black patients. the onset is often in adolescence. as hs has been under-studied historically, there is an unmet medical need to develop more effective treatment for this disease. while many patients are managed with medications and lifestyle modifications alone, a subset of hs patients benefit from surgical intervention. proper wound care following hs surgery is paramount, as facilitating proper healing and minimizing infection can prevent post-operative complications, morbidity and the need for future procedures. while many physicians continue to use wet-to-dry dressings as the standard of care for hs patients post-operatively, it is likely that the drawbacks of this dressing technique outweigh the benefits. this study hopes to answer the question of whether or not wet-to-dry dressings should truly be standard of care or whether an alternate form of wound dressings, such as petrolatum with non-stick bandaging, is at least equitable if not superior in effect, and associated with fewer drawbacks such as associated pain and time dedicated to dressing changes. this study will be a randomized, single-blind trial of two postoperative bandaging techniques: wet-to-dry dressings vs. petrolatum with non-stick bandaging. primary outcomes will be tracked using the photographic wound assessment tool (pwat), pressure ulcer scale of healing (push) tool, and wound quality of life (qol) survey. there is potential for this study to apply to surgical interventions outside of hs, as the study addresses the bandaging technique (wet-to-dry) that is standard of care after many surgical procedures.


Eligibility criteria:
inclusion criteria: * male \& females \> or = 16 years of age * patient must have undergone a standard-of-care surgical procedure for hs with planned secondary intention healing of the wound. * must be able to provide adequate informed consent for themselves * patient must be capable of performing either of the recommended wound care regimens on their own or have someone available to consistently assist with wound care. exclusion criteria: * patients with surgically closed wounds (sutures, staples) * patients with preference for specific types of bandaging protocols * patients that have not been able to tolerate either wet-to-dry or petrolatum and non-stick bandages in the past
safety of nnc 0172-0000-2021 in healthy male subjects and subjects with haemophilia a or b

Conditions: Congenital Bleeding Disorder; Haemophilia A; Haemophilia B; Healthy

Summary: this trial is conducted in europe and asia. the aim of this clinical trial is to investigate the safety, pharmacokinetics (how the trial drug is distributed in the body) and pharmacodynamics (physiological effects of the drug on the body) of nnc 0172-0000-2021 administered intravenously and subcutaneously to healthy male subjects and subjects with haemophilia a or b


Eligibility criteria:
inclusion criteria: * body weight between 50 and 100 kg, both inclusive * body mass index (bmi) between 18.0 kg/m2 and 25.0 kg/m2, both inclusive * for haemophilia subjects only: diagnosed with severe haemophilia a or b exclusion criteria: * known or suspected hypersensitivity to trial product(s) or related products * surgery planned to occur during the trial * any major and/or orthopaedic surgery within 30 days prior to trial product administration
fever and neutropenia in pediatric oncology patients

Conditions: Fever; Neutropenia

Summary: it is possible to distinguish between pediatric oncology patients who are at high or low risk for serious infection during periods of fever and treatment related neutropenia based on clinical parameters. patients with low risk can be safely treated as outpatients primarily using oral antibiotics. it is possible to improve methods of risk stratification through the addition of genomic and proteomic factors.

outpatient management of patients considered to be at low risk for serious bacterial infection has been explored using risk stratification schema based on clinical parameters. first, patients will be stratified based on a clinical risk stratification schema. patients stratified to the low risk group will be randomized between treatment using standard inpatient intravenous antibiotic therapy or outpatient antibiotic therapy using primarily an oral regimen. second, an evaluation of proteins important to the innate immune system will be performed to provide a molecular characterization of episodes based on etiology. third, single nucleotide polymorphisms in genes important for innate immunity will be evaluated to determine effect of each on infection risk during treatment induced neutropenia. finally, we will develop a bank of both plasma and dna specimens correlated with clinical outcomes for future use.

Eligibility criteria:
inclusion criteria: 1. any pediatric patient age \<21 years with an oncology diagnosis who is undergoing therapy and is expected to have treatment related neutropenia. exclusion criteria: 1. any patient who has previously undergone autologous or allogeneic bone marrow transplant will be excluded from study enrollment. if a patient is expected to undergo autologous or allogeneic bone marrow transplant as part of therapy at some point after enrollment in the study he/she will be removed from the study at the start of their bone marrow transplant. 2. any patient with a documented allergy to levofloxacin or any other fluoroquinolone will be excluded. 3. patients with a known pregnancy will be excluded. 4. any patient with an underlying chronic musculoskeletal condition (ie juvenile rheumatoid arthritis, systemic lupus erythematosis etc) which may make evaluation for joint toxicity related to quinolone treatment difficult.

Keywords: pediatrics oncology outpatient therapy
cardiopulmonary rehabilitation for adolescents and adults with congenital heart disease

Conditions: Congenital Heart Disease; Heart Defects, Congenital

Summary: the hypothesis of this study is that participation in a formal cardiopulmonary rehabilitation program improves aerobic exercise capacity and quality of life over the medium term for patients with congenital heart disease with reduced exercise capacity. to test this hypothesis, subjects will be randomized to either receive a 12-week cardiopulmonary rehabilitation program or standard of care, with interval testing of aerobic capacity and other physiologic markers improved fitness, as well as assessment of quality of life.


Eligibility criteria:
inclusion criteria: * able and willing to participate in a 12-week cardiac rehabilitation program and repeated cardiopulmonary exercise testing * pvo2≤80% predicted (impaired aerobic capacity) on baseline exercise test * congenital heart disease of at least moderate complexity exclusion criteria: * cardiac intervention (cath/surg) within prior 6m * planned cardiac intervention (cath/surg) within 12m * formal cardiac rehabilitation within 24m * current/recent (delivery\<90d prior) pregnancy, planned pregnancy within 12m * active heart failure, hospitalization or major change in clinical status over prior 30d * other recent or planned events expected to have a significant impact on exercise capacity * baseline oxygen saturation \<92%

Keywords: congenital heart disease adult congenital heart disease cardiac rehabilitation cardiopulmonary rehabilitation exercise cardiopulmonary exercise testing peak vo2 quality of life
parent psychoeducation and cognitive behavior therapy for latino adolescents with depression

Conditions: Depression

Summary: this study will determine the effectiveness of adding a parent-involved intervention to cognitive behavior therapy in reducing depressive symptoms among latino adolescents with depression.

adolescent depression can have a devastating impact on social, emotional, and family functioning. cognitive behavior therapy (cbt) is the most common treatment for depression; however, not all patients respond adequately to cbt. in addition, data on the effects of cbt among ethnic minorities are limited. because latinos are the largest minority group in the united states, the development of treatments specifically designed for depressed latino youth are needed. this study will determine whether adding a psychoeducation intervention with parent involvement will be more effective in reducing depressive symptoms among latino adolescents than treatment with cbt alone. the treatment phase of this study will last 12 weeks. participants will be randomly assigned to receive 12 weeks of either cbt alone or cbt with psychoeducation. the psychoeducation will consist of 8 sessions over the 12-week treatment period. during the sessions, participants and their parents will be given detailed information about depression and ways the condition can be treated. they will also be taught coping skills and ways to recognize a relapse. cbt sessions will take place weekly during the study. during the sessions, a therapist will work with participants to modify the behavior and thinking patterns that cause and are associated with their depressive symptoms. both participants and their parents will undergo interviews at study start, study completion, and 3, 9, and 15 months after study completion. during the interviews, participants' depressive symptoms, school attendance, and overall functional status will be assessed. parents' stress levels and work attendance will also be assessed. at months 6 and 12 after study completion, participants and their parents will complete questionnaires to assess any relapses in depressive symptoms. study hypothesis: active treatment with psychoeducation will be superior to no psychoeducation in reducing depression post-treatment. because the psychoeducation intervention is designed to involve parents and thus impact other aspects of the family system, the treatment is expected to produce better outcomes in several functional domains.

Eligibility criteria:
inclusion criteria: * diagnosis of depression * parent or guardian willing to provide informed consent exclusion criteria: * psychiatric conditions other than depression

Keywords: adolescent cbt parents
towards improved diagnostics for suspected platelet function disorders

Conditions: Platelet Function Disorder; Platelet Disorder; Thrombocytopathy

Summary: this study aims to improve platelet function testing during bleeding investigations. to this end, the study will evaluate the diagnostic accuracy of novel platelet function tests in patients with confirmed or suspected platelet function disorders. study participants will be recruited from patients that are referred to or treated at the coagulation unit, karolinska university hospital, and pediatric coagulation unit, astrid lingren children's hospital.


Eligibility criteria:
inclusion criteria, known defects: * known platelet function disorder under follow-up at karolinska university hospital (genetic or functional assay) * high likelihood of platelet function disorder (aberrant screening test with inheritance) * family investigation for platelet disorder exclusion criteria, known defects:: * antiplatelet or anticoagulant drugs * vwf:gpib below 0.40 iu/ml * hematocrit below 0.35 or above 0.50 * other coagulation disorder inclusion criteria, suspected platelet function disorder: * bleeding investigation at karolinska university hospital exclusion criteria, suspected platelet function disorder:: * antiplatelet or anticoagulant drugs * vwf:gpib below 0.40 iu/ml * hematocrit below 0.35 or above 0.50 * other coagulation disorder

Keywords: diagnostic accuracy
enhanced nutrition for preterm infants

Conditions: Preterm Birth

Summary: the overall objective of the proposal is to demonstrate the feasibility of providing increased calories and protein in the first week of life to very low birth weight (vlbw) preterm infants.

infants will be randomized to receive either standard parenteral nutrition via the neonatal intensive care unit (nicu) protocol or enhanced parenteral nutrition via the study protocol during their first week of life through higher initial macronutrient provision and faster advancement of macronutrient provision.

Eligibility criteria:
inclusion criteria: * vlbw (birth weight \<1500grams) preterm (gestational age (ga) at birth \< 32 weeks) infants admitted to the university of minnesota masonic children's hospital nicu, for which written informed consent can be secured from a parent within 12 hours of birth. exclusion criteria: * infants who are diagnosed prenatally with a clinical condition (other than prematurity) that is known to affect growth rate, adiposity, or neurocognitive development, who experienced severe birth asphyxia, who are enrolled in another study affecting nutritional management, or who are likely to be transferred out of the nicu will be excluded from participation.

Keywords: nutrition body composition preterm neonate
tb immunotherapy trial with heat-killed m. vaccae

Conditions: Tuberculosis

Summary: the purpose of the study is to carry out multi-country (ukraine and mongolia), placebo-controlled, randomized phase iii trial in patients with drug-sensitive, multi-drug resistant (mdr-tb) and tb-hiv and identify efficacy and safety of whole-cell, heat-killed mycobacterium vaccae formulated as a pill (v7) and consequently conduct confirmatory trials in intended registration countries, such as china, russia and south africa, etc.

main end-point is negative sputum conversion rate after one month in patients on v7 vs placebo arm, both arms will receive conventional anti-tuberculosis chemotherapy consisting of 1st and/or 2nd line tb drugs according to baseline diagnosis

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of tb * sputum smear positive exclusion criteria: * pregnant * likely to be non-compliant due to drug and/or alcohol abuse * mentally unfit to comply with treatment

Keywords: m. vaccae tb mdr-tb v7-immunitor